Open AccessInvestigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent
Author(s) -
Jeffry D. Shearer,
Gary W. Wolfe,
Aruna Sampath,
Kelly L. Warfield,
Brian Kaufman,
Urban Ramstedt,
Anthony M. Treston
Publication year - 2022
Publication title -
international journal of toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 58
eISSN - 1092-874X
pISSN - 1091-5818
DOI - 10.1177/10915818211072842
Subject(s) - safety pharmacology , herg , pharmacology , drug , medicine , adverse effect , phospholipidosis , broad spectrum , biology , potassium channel , chemistry , combinatorial chemistry , phospholipid , membrane , genetics
UV-4 (N-(9-methoxynonyl)-1-deoxynojirimycin) is a broad-spectrum antiviral drug candidate with demonstrated activity in vitro and in vivo against multiple, diverse viruses. Nonclinical safety pharmacology studies were conducted to support the filing of an Investigational New Drug (IND) application. Preliminary in vitro pharmacology testing evaluating potential for binding to "off-target" receptors and enzymes indicated no significant liability for advanced development of UV-4. The safety pharmacology of UV-4 was evaluated in the in vitro human ether-à-go-go-related gene (hERG) assay, in a central nervous system (CNS) study in the mouse (modified Irwin test), in a respiratory safety study in conscious mice using whole body plethysmography, and in a cardiovascular safety study in conscious, radiotelemetry-instrumented beagle dogs. There were no observed adverse treatment-related effects following administration of UV-4 as the hydrochloride salt in the hERG potassium channel assay, on respiratory function, in the CNS study, or in the cardiovascular assessment. Treatment-related cardiovascular effect of decreased arterial pulse pressure after 50 or 200 mg of UV-4/kg was the only change outside the normal range, and all hemodynamic parameters returned to control levels by the end of the telemetry recording period. These nonclinical safety pharmacology assessments support the evaluation of this host-targeted broad-spectrum antiviral drug candidate in clinical studies.